Overactive Bladder Treatment Market

Market Leader - Overactive Bladder Treatment Market

The global overactive bladder treatment market is projected to reach USD 4.19 Billion by 2022 from USD 3.63 Billion in 2017, at a CAGR of 2.9% during the forecast period. This market is consolidated in nature with a few regional and national players. In 2016, Astellas Pharma, Inc. (Japan) and Pfizer, Inc. (U.S.) dominated the overactive bladder treatment market and accounted for approximately 60% to 70% share of the overall market

Astellas Pharma, Inc. dominated the global overactive bladder treatment market in 2016. The company offers two patented drugs, namely, VESIcare (solifenacin) and BETMIGA (mirabegron) in the market. VESIcare is the blockbuster drug offered by the company to maintain its leadership position in the overactive bladder treatment market owing to its high efficacy as compared to other oral treatments. Astellas’ “Creating Innovation” strategy, backed by its R&D wing, helps identify new therapeutic areas as well as new solutions for existing areas. Its robust pipeline is a result of high R&D investment over the years. As of April 2017, Astellas has 47 molecular and biological entities in the clinical pipeline.

Pfizer, Inc. held the second position in the global overactive bladder treatment market in 2016. Its blockbuster drugs—Detrol and Toviaz—have generated high revenues for the company in the overactive bladder treatment market. The company adopts an aggressive marketing strategy for OAB treatment products, “GottaGo” and “YourWay” are the prominent ones. Pfizer employed Mesmerize Marketing for an unbranded campaign, to drive traffic to its website, overactivebladder.com. The company also introduced a free 12-week program designed to help physicians educate patients on bladder overactivity. Pfizer is also a major innovator in the pharma industry with 96 projects in its pipeline.

Some of the other players competing in this market are Allergan, Plc. (Ireland), Teva Pharmaceutical Industries Limited (Israel), Mylan N.V. (U.S.), Medtronic plc (Ireland), Endo International plc (Ireland), and Sanofi (France).

Related Reports:

Overactive Bladder Treatment Market by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Overactivity) - Global Forecast to 2022

Contact:
Mr. Rohan
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 
[email protected]

Report Code
PH 5449
RI Published ON
7/28/2017
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Overactive Bladder Treatment Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved